Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

Similar articles for PubMed (Select 23581945)

1.

The use, misuse and abuse of dabigatran.

Attia JR, Pearce R.

Med J Aust. 2013 Apr 15;198(7):356-7.

PMID:
23581945
2.

Is there really misuse and abuse of dabigatran?

Eikelboom JW, Hankey GJ.

Med J Aust. 2013 Apr 15;198(7):358-9. No abstract available.

PMID:
23581946
3.

[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].

Shevelev VI, Kanorskiń≠ SG.

Kardiologiia. 2012;52(7):56-60. Russian.

PMID:
22839715
4.

Dabigatran: life-threatening bleeding.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):41-3. Review.

PMID:
23444501
5.

Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.

Ali A, Bailey C, Abdelhafiz AH.

Age Ageing. 2012 Sep;41(5):681-4. doi: 10.1093/ageing/afs017. Epub 2012 Feb 28.

6.

The trouble with dabigatran.

Charlton B, Redberg R.

BMJ. 2014 Jul 23;349:g4681. doi: 10.1136/bmj.g4681. No abstract available.

PMID:
25055830
7.

Dabigatran, bleeding, and the regulators.

Moore TJ, Cohen MR, Mattison DR.

BMJ. 2014 Jul 23;349:g4517. doi: 10.1136/bmj.g4517. No abstract available.

PMID:
25056265
8.

Dabigatran "non-inferior" to warfarin, but only just.

[No authors listed]

BMJ. 2013 Feb 27;346:f1219. doi: 10.1136/bmj.f1219. No abstract available.

PMID:
23447339
9.

Dabigatran and postmarketing reports of bleeding.

Southworth MR, Reichman ME, Unger EF.

N Engl J Med. 2013 Apr 4;368(14):1272-4. doi: 10.1056/NEJMp1302834. Epub 2013 Mar 13. No abstract available.

10.

Concerns over data in key dabigatran trial.

Cohen D.

BMJ. 2014 Jul 23;349:g4747. doi: 10.1136/bmj.g4747. No abstract available.

PMID:
25055831
11.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
12.

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.

Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L; RE-DEEM Investigators.

Eur Heart J. 2011 Nov;32(22):2781-9. doi: 10.1093/eurheartj/ehr113. Epub 2011 May 7.

13.

Avoiding adverse events with dabigatran by careful selection of eligible patients.

Baker RI, Harper P, McLintock C.

Med J Aust. 2012 Apr 16;196(7):431-2. No abstract available.

PMID:
22509863
14.

Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.

Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.

J Stroke Cerebrovasc Dis. 2012 Apr;21(3):165-73. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.011. Review.

PMID:
22440950
15.

Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors.

Artang R, Rome E, Nielsen JD, Vidaillet HJ.

Am J Cardiol. 2013 Dec 15;112(12):1973-9. doi: 10.1016/j.amjcard.2013.08.027. Epub 2013 Sep 25.

16.

Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.

Baumann Kreuziger LM, Reding MT.

Thromb Res. 2013 Aug;132(2):e161-3. doi: 10.1016/j.thromres.2013.07.011. Epub 2013 Jul 31. No abstract available.

17.

[Dabigatran, a new oral anticoagulant].

Uchiyama S.

Brain Nerve. 2011 Apr;63(4):411-5. Review. Japanese.

PMID:
21441645
18.

Risk of major bleeding and the standard doses of dabigatran.

Antoniazzi S, Berda√Į D, Conti V, Clementi E, Salvo F.

Eur J Intern Med. 2014 Jul;25(6):e73-5. doi: 10.1016/j.ejim.2014.02.005. Epub 2014 Mar 11. No abstract available.

PMID:
24629895
19.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

Kamel H, Johnston SC, Easton JD, Kim AS.

Stroke. 2012 Mar;43(3):881-3. doi: 10.1161/STROKEAHA.111.641027. Epub 2012 Feb 3.

20.

Dabigatran: how the drug company withheld important analyses.

Cohen D.

BMJ. 2014 Jul 23;349:g4670. doi: 10.1136/bmj.g4670. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk